APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Influenza Vaccine

Influenza vaccines, also known as flu shots, are vaccines that protect against influenza. A new version of the vaccine is developed twice a year as the influenza virus rapidly changes. Most provide modest to high protection against influenza; however, each year this varies. Evidence in adults over 65 years old is poor. They decrease the number of missed days of work by a half day on average. Vaccinating children may protect those around them.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Influenza vaccines, also known as flu shots, are vaccines that protect against influenza. A new version of the vaccine is developed twice a year as the influenza virus rapidly changes. Most provide modest to high protection against influenza; however, each year this varies. Evidence in adults over 65 years old is poor. They decrease the number of missed days of work by a half day on average. Vaccinating children may protect those around them.

Selected research

Market Outlook & Growth Opportunities

Global Influenza Vaccine Market Outlook and Growth Opportunities 2026

Report ID 174002710421 December 2025193 pages

Choose your research edition.

Industry ResearchInfluenza Vaccine Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Influenza Vaccine Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Influenza Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Influenza Vaccine Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Influenza Vaccine Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

Influenza vaccines, also known as flu shots, are vaccines that protect against influenza. A new version of the vaccine is developed twice a year as the influenza virus rapidly changes. Most provide modest to high protection against influenza; however, each year this varies. Evidence in adults over 65 years old is poor. They decrease the number of missed days of work by a half day on average. Vaccinating children may protect those around them.

Global Influenza Vaccine main players include CSL, GSK, Sanofi Pasteur, Mylan, Hulan Bio, AstraZeneca, CCBIO, etc., totally accounting for about 95% of market. North America is the largest market of Influenza Vaccine, with a share over 55%. As for the types of products, it can be divided into Trivalent Influenza Vaccine and Quadrivalent Influenza Vaccine. The most common product is Quadrivalent Influenza Vaccine, with a share over 95%. In terms of applications, it is widely used in For Children (6 months to 3 years) and For Adults and Children over 3 years. The most application is in Adults and Children over 3 years, with a share over 73%.

This report provides an overview of the global Influenza Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Influenza Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Influenza Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Influenza Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Influenza Vaccine Segment by Company

CSL

GSK

Sanofi Pasteur

Mylan

Hulan Bio

AstraZeneca

CCBIO

Influenza Vaccine Segment by Type

Trivalent Influenza Vaccine

Quadrivalent Influenza Vaccine

Influenza Vaccine Segment by Application

For Children (6 months to 3 years)

For Adults and Children over 3 years

Influenza Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Influenza Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Influenza Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Influenza Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Influenza Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenza Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Influenza Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenza Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Influenza Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Influenza Vaccine industry.

Chapter 3: Detailed analysis of Influenza Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Influenza Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Influenza Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Influenza Vaccine Industry Trends Table 2. Influenza Vaccine Industry Drivers Table 3. Influenza Vaccine Industry Opportunities and Challenges Table 4. Influenza Vaccine Industry Restraints Table 5. Global Influenza Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Influenza Vaccine Revenue Share by Company (2021-2026) Table 7. Global Influenza Vaccine Sales Volume by Company (M Doses) & (2021-2026) Table 8. Global Influenza Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Influenza Vaccine Average Price (USD/Doses) of Company (2021-2026) Table 10. Global Influenza Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Influenza Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Influenza Vaccine Company, Product Type & Application Table 13. Global Influenza Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Influenza Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Trivalent Influenza Vaccine Table 18. Significant Companies of Quadrivalent Influenza Vaccine Table 19. Global Influenza Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (M Doses) Table 20. Global Influenza Vaccine Sales Volume by Type (2021-2026) & (M Doses) Table 21. Global Influenza Vaccine Sales Volume by Type (2027-2032) & (M Doses) Table 22. Global Influenza Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Influenza Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Influenza Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Influenza Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Influenza Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Influenza Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Influenza Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of For Children (6 months to 3 years) Table 30. Significant Companies of For Adults and Children over 3 years Table 31. Global Influenza Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (M Doses) Table 32. Global Influenza Vaccine Sales Volume by Application (2021-2026) & (M Doses) Table 33. Global Influenza Vaccine Sales Volume by Application (2027-2032) & (M Doses) Table 34. Global Influenza Vaccine Sales Volume Share by Application (2021-2026) Table 35. Global Influenza Vaccine Sales Volume Share by Application (2027-2032) Table 36. Global Influenza Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Influenza Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Influenza Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Influenza Vaccine Sales Value Share by Application (2021-2026) Table 40. Global Influenza Vaccine Sales Value Share by Application (2027-2032) Table 41. Global Influenza Vaccine Sales by Region: 2021 VS 2025 VS 2032 (M Doses) Table 42. Global Influenza Vaccine Sales by Region (2021-2026) & (M Doses) Table 43. Global Influenza Vaccine Sales Market Share by Region (2021-2026) Table 44. Global Influenza Vaccine Sales by Region (2027-2032) & (M Doses) Table 45. Global Influenza Vaccine Sales Market Share by Region (2027-2032) Table 46. Global Influenza Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Influenza Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Influenza Vaccine Sales Value Share by Region (2021-2026) Table 49. Global Influenza Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Influenza Vaccine Sales Value Share by Region (2027-2032) Table 51. Global Influenza Vaccine Market Average Price (USD/Doses) by Region (2021-2026) Table 52. Global Influenza Vaccine Market Average Price (USD/Doses) by Region (2027-2032) Table 53. Global Influenza Vaccine Sales by Country: 2021 VS 2025 VS 2032 (M Doses) Table 54. Global Influenza Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Influenza Vaccine Sales by Country (2021-2026) & (M Doses) Table 56. Global Influenza Vaccine Sales Market Share by Country (2021-2026) Table 57. Global Influenza Vaccine Sales by Country (2027-2032) & (M Doses) Table 58. Global Influenza Vaccine Sales Market Share by Country (2027-2032) Table 59. Global Influenza Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Influenza Vaccine Sales Value Market Share by Country (2021-2026) Table 61. Global Influenza Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Influenza Vaccine Sales Value Market Share by Country (2027-2032) Table 63. CSL Company Information Table 64. CSL Business Overview Table 65. CSL Influenza Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 66. CSL Influenza Vaccine Product Portfolio Table 67. CSL Recent Development Table 68. GSK Company Information Table 69. GSK Business Overview Table 70. GSK Influenza Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 71. GSK Influenza Vaccine Product Portfolio Table 72. GSK Recent Development Table 73. Sanofi Pasteur Company Information Table 74. Sanofi Pasteur Business Overview Table 75. Sanofi Pasteur Influenza Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 76. Sanofi Pasteur Influenza Vaccine Product Portfolio Table 77. Sanofi Pasteur Recent Development Table 78. Mylan Company Information Table 79. Mylan Business Overview Table 80. Mylan Influenza Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 81. Mylan Influenza Vaccine Product Portfolio Table 82. Mylan Recent Development Table 83. Hulan Bio Company Information Table 84. Hulan Bio Business Overview Table 85. Hulan Bio Influenza Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 86. Hulan Bio Influenza Vaccine Product Portfolio Table 87. Hulan Bio Recent Development Table 88. AstraZeneca Company Information Table 89. AstraZeneca Business Overview Table 90. AstraZeneca Influenza Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 91. AstraZeneca Influenza Vaccine Product Portfolio Table 92. AstraZeneca Recent Development Table 93. CCBIO Company Information Table 94. CCBIO Business Overview Table 95. CCBIO Influenza Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 96. CCBIO Influenza Vaccine Product Portfolio Table 97. CCBIO Recent Development Table 98. Key Raw Materials Table 99. Raw Materials Key Suppliers Table 100. Influenza Vaccine Distributors List Table 101. Influenza Vaccine Customers List Table 102. Research Programs/Design for This Report Table 103. Authors List of This Report Table 104. Secondary Sources Table 105. Primary Sources List of Figures Figure 1. Influenza Vaccine Product Image Figure 2. Global Influenza Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Influenza Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Influenza Vaccine Sales (2021-2032) & (M Doses) Figure 5. Global Influenza Vaccine Sales Average Price (USD/Doses) & (2021-2032) Figure 6. Global Influenza Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Trivalent Influenza Vaccine Image Figure 10. Quadrivalent Influenza Vaccine Image Figure 11. Global Influenza Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (M Doses) Figure 12. Global Influenza Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Influenza Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Influenza Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Influenza Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Influenza Vaccine Sales Value Share by Type (2021-2032) Figure 17. For Children (6 months to 3 years) Image Figure 18. For Adults and Children over 3 years Image Figure 19. Global Influenza Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (M Doses) Figure 20. Global Influenza Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Influenza Vaccine Sales Volume Share by Application (2021-2032) Figure 22. Global Influenza Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Influenza Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Influenza Vaccine Sales Value Share by Application (2021-2032) Figure 25. Global Influenza Vaccine Sales by Region: 2021 VS 2025 VS 2032 (M Doses) Figure 26. Global Influenza Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Influenza Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Influenza Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Influenza Vaccine Sales Value (2021-2032) & (US$ Million) Figure 30. North America Influenza Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Influenza Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Influenza Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Influenza Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Influenza Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Influenza Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. South America Influenza Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Influenza Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Influenza Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Influenza Vaccine Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Influenza Vaccine Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Trivalent Influenza Vaccine
  • Quadrivalent Influenza Vaccine
Applications
  • For Children (6 months to 3 years)
  • For Adults and Children over 3 years
Companies covered
  • CSL
  • GSK
  • Sanofi Pasteur
  • Mylan
  • Hulan Bio
  • AstraZeneca
  • CCBIO

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Influenza Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Influenza Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Influenza Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Influenza Vaccine Market Dynamics
  1. 2.1 Influenza Vaccine Industry Trends
  2. 2.2 Influenza Vaccine Industry Drivers
  3. 2.3 Influenza Vaccine Industry Opportunities and Challenges
  4. 2.4 Influenza Vaccine Industry Restraints
3 Influenza Vaccine Market by Company
  1. 3.1 Global Influenza Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Influenza Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Influenza Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Influenza Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Influenza Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Influenza Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Influenza Vaccine Company Product Type and Application
  8. 3.8 Global Influenza Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Influenza Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Influenza Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Influenza Vaccine Market by Type
  1. 4.1 Influenza Vaccine Type Introduction
  2. 4.1.1 Trivalent Influenza Vaccine
  3. 4.1.2 Quadrivalent Influenza Vaccine
  4. 4.2 Global Influenza Vaccine Sales Volume by Type
  5. 4.2.1 Global Influenza Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Influenza Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Influenza Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Influenza Vaccine Sales Value by Type
  9. 4.3.1 Global Influenza Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Influenza Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Influenza Vaccine Sales Value Share by Type (2021-2032)
5 Influenza Vaccine Market by Application
  1. 5.1 Influenza Vaccine Application Introduction
  2. 5.1.1 For Children (6 months to 3 years)
  3. 5.1.2 For Adults and Children over 3 years
  4. 5.2 Global Influenza Vaccine Sales Volume by Application
  5. 5.2.1 Global Influenza Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Influenza Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Influenza Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Influenza Vaccine Sales Value by Application
  9. 5.3.1 Global Influenza Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Influenza Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Influenza Vaccine Sales Value Share by Application (2021-2032)
6 Influenza Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Influenza Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Influenza Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Influenza Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Influenza Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Influenza Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Influenza Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Influenza Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Influenza Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Influenza Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Influenza Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Influenza Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Influenza Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Influenza Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Influenza Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Influenza Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Influenza Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Influenza Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Influenza Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Influenza Vaccine Sales Value Share by Country, 2025 VS 2032
7 Influenza Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Influenza Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Influenza Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Influenza Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Influenza Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Influenza Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Influenza Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Influenza Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Influenza Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Influenza Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Influenza Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Influenza Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Influenza Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Influenza Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Influenza Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Influenza Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Influenza Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Influenza Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Influenza Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Influenza Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Influenza Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Influenza Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Influenza Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Influenza Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Influenza Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Influenza Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Influenza Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Influenza Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Influenza Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Influenza Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Influenza Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Influenza Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Influenza Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Influenza Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Influenza Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Influenza Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Influenza Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 CSL
  2. 8.1.1 CSL Company Information
  3. 8.1.2 CSL Business Overview
  4. 8.1.3 CSL Influenza Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 CSL Influenza Vaccine Product Portfolio
  6. 8.1.5 CSL Recent Developments
  7. 8.2 GSK
  8. 8.2.1 GSK Company Information
  9. 8.2.2 GSK Business Overview
  10. 8.2.3 GSK Influenza Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 GSK Influenza Vaccine Product Portfolio
  12. 8.2.5 GSK Recent Developments
  13. 8.3 Sanofi Pasteur
  14. 8.3.1 Sanofi Pasteur Company Information
  15. 8.3.2 Sanofi Pasteur Business Overview
  16. 8.3.3 Sanofi Pasteur Influenza Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Pasteur Influenza Vaccine Product Portfolio
  18. 8.3.5 Sanofi Pasteur Recent Developments
  19. 8.4 Mylan
  20. 8.4.1 Mylan Company Information
  21. 8.4.2 Mylan Business Overview
  22. 8.4.3 Mylan Influenza Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Mylan Influenza Vaccine Product Portfolio
  24. 8.4.5 Mylan Recent Developments
  25. 8.5 Hulan Bio
  26. 8.5.1 Hulan Bio Company Information
  27. 8.5.2 Hulan Bio Business Overview
  28. 8.5.3 Hulan Bio Influenza Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Hulan Bio Influenza Vaccine Product Portfolio
  30. 8.5.5 Hulan Bio Recent Developments
  31. 8.6 AstraZeneca
  32. 8.6.1 AstraZeneca Company Information
  33. 8.6.2 AstraZeneca Business Overview
  34. 8.6.3 AstraZeneca Influenza Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 AstraZeneca Influenza Vaccine Product Portfolio
  36. 8.6.5 AstraZeneca Recent Developments
  37. 8.7 CCBIO
  38. 8.7.1 CCBIO Company Information
  39. 8.7.2 CCBIO Business Overview
  40. 8.7.3 CCBIO Influenza Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 CCBIO Influenza Vaccine Product Portfolio
  42. 8.7.5 CCBIO Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Influenza Vaccine Value Chain Analysis
  2. 9.1.1 Influenza Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Influenza Vaccine Sales Mode & Process
  6. 9.2 Influenza Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Influenza Vaccine Distributors
  9. 9.2.3 Influenza Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst